Guide

Pharmaceutical GMP readiness in China

China's drug framework is set by the Drug Administration Law (2019 revision) and the Provisions for Drug Registration (2020). The National Medical Products Administration (NMPA) regulates drugs; the Center for Food and Drug Inspection (CFDI / NIFDC) conducts GMP inspections. China-GMP (2010, with subsequent revised annexes including the 2020 Annex on Data Integrity) is technically aligned with EudraLex Vol 4 / WHO TRS but is enforced independently — China is an ICH member since 2017 but is NOT a PIC/S member. Marketing requires an MAH established in China. This guide covers the China-specific layer.

Start free trial Free trial, no credit card, onboard in days, not months.

Regulator and legal basis

NMPA sits under the State Administration for Market Regulation. CDE handles registration review; CFDI conducts GMP inspections; provincial MPAs license domestic sites. Statutory base: Drug Administration Law 2019; Provisions for Drug Registration 2020; 2010 GMP plus revised annexes (sterile, biologicals, APIs, TCM, IMPs, data integrity).

MAH system and imported drugs

The MAH (Marketing Authorization Holder) system, introduced nationally in 2019, separates the licence holder from the manufacturer. Foreign manufacturers cannot hold the MAH directly — they appoint a designated Chinese legal entity as the MAH agent. Imported drugs require an Imported Drug Licence (IDL) and on-site inspection of the foreign manufacturing site by CFDI.

Drug code, language, and labelling

China operates a national drug electronic supervision code (药品电子监管码) — a unique identifier on saleable packs reported through the NMPA hub for high-risk classes (vaccines fully; broader categories being phased in). All labelling and IFU must be in simplified Chinese; submissions are in Chinese with English supporting allowed.

Inspection style and common findings

CFDI inspections are intensive and often unannounced. Outcomes feed into licence retention and may trigger product recall. Common findings: data integrity (the 2020 annex is enforced strictly), deviation/CAPA, sterile/Annex 1 equivalent contamination control, and supplier qualification of imported APIs. China is not in PIC/S — EU/US inspection reports are referenced but not formally relied upon.

A 90–180 day China readiness path

Days 0–30: appoint MAH agent; identify IDL scope and product registrations. Days 31–90: align documentation to 2010 GMP and the data-integrity annex; prepare simplified Chinese labelling. Days 91–180: pre-inspection readiness with bilingual records; host CFDI inspection. Plan 6–18 months for full registration timelines.

Standards covered in this guide

Each standard, retailer code or assurance scheme referenced above has its own deep-dive page with scope, audit detail and common pitfalls.

EU Annex 11

Annex 11 defines how GMP computerized systems must be validated, controlled, and monitored to protect product quality and patient safety across the EU, with strong data integrity and lifecycle expectations.

EU GMP Annex 1 Sterile

Annex 1 sets the modern, risk-based standard for sterile manufacturing, requiring a holistic contamination control strategy, robust aseptic operations, and documented evidence that facilities and processes consistently protect patients.

Data integrity

Data integrity ensures GxP records truly reflect what happened, guided by ALCOA plus principles and enforced through people, process, and technology controls across paper and electronic systems.

Where this lives in V5 Ultimate

The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.

Modules that do the work

Document control

Versioned SOPs, controlled artwork, periodic review with e-signatures.

QMS

CAPA, deviations, change control, management review wired together.

Audits & CAPA

Findings auto-route to owners with statutory clocks and evidence trail.

Industries this hits hardest

Frequently asked

Is China a PIC/S member?

Not as of 2026. China is an ICH member (since 2017) and has substantially converged on ICH guidelines, but NMPA inspections do not rely on PIC/S partners' GMP certificates — CFDI will inspect foreign sites for imported drugs.

Do we need a Chinese MAH or can we hold our own MA?

Foreign manufacturers cannot hold the MAH directly. A Chinese legal entity must hold the MAH role, with documented agreements covering quality oversight, pharmacovigilance, and recall responsibility.

How strict is China on data integrity?

Very. The 2020 Annex on Data Integrity codified ALCOA+ expectations; CFDI inspectors actively examine audit trails, instrument software user management, and contemporaneous records. Hybrid (paper + electronic) systems are a frequent finding area.

See it on your shop floor.

Free trial, no credit card, onboard in days, not months.

Start free trial See pricing →Browse all resources →